Search

Your search keyword '"González‐Duarte, Alejandra"' showing total 285 results

Search Constraints

Start Over You searched for: Author "González‐Duarte, Alejandra" Remove constraint Author: "González‐Duarte, Alejandra"
285 results on '"González‐Duarte, Alejandra"'

Search Results

2. Measurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study

7. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

8. Cutaneous biomarkers of therapeutic efficacy in early treatment of hereditary ATTR amyloid polyneuropathy with tafamidis.

11. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis

13. Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis

16. A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe COvid-19 (PISCO) trial protocol

17. Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay.

18. Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke: The Global COVID-19 Stroke Registry

19. Correction to: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis

20. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis: Analysis of the APOLLO Study

22. 137 PRIMARY RESULTS FROM APOLLO-B, A PHASE 3 STUDY OF PATISIRAN IN PATIENTS WITH TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH CARDIOMYOPATHY

23. Detection of sudomotor alterations evaluated by Sudoscan in patients with recently diagnosed type 2 diabetes

25. Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS)

26. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.

27. HELIOS-A: Results from the Phase 3 Study of Vutrisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy (S8.003)

28. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial

29. Vitreous involvement as initial presentation of hereditary transthyretin amyloidosis related to the rare TTR Ile107Met (p.Ile127Met) pathogenic variant

34. Characteristics and predictors for silent hypoxemia in a cohort of hospitalized COVID-19 patients

38. COVID-19-related diffuse posthypoxic leukoencephalopathy and microbleeds masquerades as acute necrotizing encephalopathy.

39. Global & Community Health: Implementation of and Patient Satisfaction With the First Neurologic Telemedicine Program in Mexico During COVID-19

40. Supplemental Data.pdf

44. HELIOS-A: 9-month Results from the Phase 3 Study of Vutrisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy (1234)

45. Neurologic manifestations in hospitalized patients with COVID-19 in Mexico City

46. Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke:The Global COVID-19 Stroke Registry

48. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

49. COVID-19-related diffuse posthypoxic leukoencephalopathy and microbleeds masquerades as acute necrotizing encephalopathy

50. Exploratory Analyses From Apollo-B, A Phase 3 Study Of Patisiran In Patients With Attr Amyloidosis With Cardiomyopathy

Catalog

Books, media, physical & digital resources